Rare disease therapy developer Homology Medicines has raised approximately $130m in VC funding from investors including Novartis.
Homology Medicines, a US-based genetic disease drug developer backed by pharmaceutical company Novartis, has filed for a $100m initial public offering on the Nasdaq Global Select Market.
Homology is developing gene therapies intended to treat the underlying causes of rare genetic diseases. Part of the IPO proceeds will be used to take its lead gene therapy candidate, HMI-102, through preclinical studies and a phase 1/2 clinical trial.
The funds raised through the offering will also support the advance of…
